UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA.
Department of Neurology, University of California San Francisco, San Francisco, CA.
Ann Neurol. 2018 Jul;84(1):51-63. doi: 10.1002/ana.25263. Epub 2018 Jul 3.
Primary progressive multiple sclerosis (PPMS) causes accumulation of neurological disability from disease onset without clinical attacks typical of relapsing multiple sclerosis (RMS). However, whether genetic variation influences the disease course remains unclear. We aimed to determine whether mutations causative of neurological disorders that share features with multiple sclerosis (MS) contribute to risk for developing PPMS.
We examined whole-genome sequencing (WGS) data from 38 PPMS and 81 healthy subjects of European ancestry. We selected pathogenic variants exclusively found in PPMS patients that cause monogenic neurological disorders and performed two rounds of replication genotyping in 746 PPMS, 3,049 RMS, and 1,000 healthy subjects. To refine our findings, we examined the burden of rare, potentially pathogenic mutations in 41 genes that cause hereditary spastic paraplegias (HSPs) in PPMS (n = 314), secondary progressive multiple sclerosis (SPMS; n = 587), RMS (n = 2,248), and healthy subjects (n = 987) genotyped using the MS replication chip.
WGS and replication studies identified three pathogenic variants in PPMS patients that cause neurological disorders sharing features with MS: KIF5A p.Ala361Val in spastic paraplegia 10; MLC1 p.Pro92Ser in megalencephalic leukodystrophy with subcortical cysts, and REEP1 c.606 + 43G>T in Spastic Paraplegia 31. Moreover, we detected a significant enrichment of HSP-related mutations in PPMS patients compared to controls (risk ratio [RR] = 1.95; 95% confidence interval [CI], 1.27-2.98; p = 0.002), as well as in SPMS patients compared to controls (RR = 1.57; 95% CI, 1.18-2.10; p = 0.002). Importantly, this enrichment was not detected in RMS.
This study provides evidence to support the hypothesis that rare Mendelian genetic variants contribute to the risk for developing progressive forms of MS. Ann Neurol 2018;83:51-63.
原发性进行性多发性硬化症(PPMS)在无复发多发性硬化症(RMS)典型临床发作的情况下,从疾病发病开始就导致神经功能障碍逐渐积累。然而,遗传变异是否会影响疾病进程仍不清楚。我们旨在确定是否与多发性硬化症(MS)具有相似特征的神经障碍的致病突变会增加发展为原发性进行性多发性硬化症(PPMS)的风险。
我们检查了 38 名 PPMS 和 81 名欧洲血统健康受试者的全基因组测序(WGS)数据。我们选择仅在 PPMS 患者中发现的引起单基因神经障碍的致病变异,并在 746 名 PPMS、3049 名 RMS 和 1000 名健康受试者中进行了两轮复制基因分型。为了完善我们的发现,我们在 41 个导致遗传性痉挛性截瘫(HSP)的基因中检查了罕见的、潜在致病性突变的负担,在 314 名原发性进行性多发性硬化症(PPMS)、587 名继发性进行性多发性硬化症(SPMS)、2248 名 RMS 和 987 名健康受试者中使用 MS 复制芯片进行了基因分型。
WGS 和复制研究在 PPMS 患者中鉴定出三种导致具有 MS 特征的神经障碍的致病变异:在痉挛性截瘫 10 中 KIF5A p.Ala361Val;在巨脑白质营养不良伴皮质下囊肿中 MLC1 p.Pro92Ser;以及在痉挛性截瘫 31 中 REEP1 c.606+43G>T。此外,与对照组相比,我们在 PPMS 患者中检测到 HSP 相关突变显著富集(风险比[RR] = 1.95;95%置信区间[CI],1.27-2.98;p = 0.002),与对照组相比,SPMS 患者也存在这种富集(RR = 1.57;95%CI,1.18-2.10;p = 0.002)。重要的是,在 RMS 中未检测到这种富集。
这项研究提供了证据支持这样的假设,即罕见的孟德尔遗传变异会增加发展进行性多发性硬化症的风险。